Phenothiazine Synthesis via Reductive Amination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional methods for synthesizing thionine and thioninium compounds, such as those used in treating Alzheimer's disease, often result in products with residual chromium impurities, requiring extensive purification and using chromium-based oxidizing agents, which is undesirable.
Innovation Solution
A method involving selective alkylation by reductive amination to synthesize substituted 10H-phenothiazine-3,7-diamine compounds without using chromium oxidizing agents, ensuring minimal residual chromium and improved purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If chromium-based oxidizing agents are used in conventional synthesis methods, then the synthesis process is straightforward and well-established, but residual chromium impurities remain in the product requiring extensive purification
Solution Approach 1:
The invention extracts and removes the harmful chromium-based oxidizing agents from the synthesis process entirely, replacing them with chromium-free alternatives. This eliminates the source of chromium impurities at the outset, allowing straightforward synthesis without subsequent extensive purification steps to remove residual chromium.
Solution Approach 2:
The invention changes the chemical parameters of the oxidation process by substituting chromium-based reagents with alternative oxidizing agents that do not contain chromium. This parameter change maintains the effectiveness of the oxidation step while eliminating the harmful impurity generation, achieving both high purity and process simplicity.
2Reliability
If chromium-based oxidizing agents are used, then the oxidation step is effective and reliable, but extensive purification steps are required to remove residual chromium
Solution Approach 1:
The invention converts the potential harm of chromium contamination into a benefit by using chromium-free oxidizing agents. This prevents the formation of harmful residues from the beginning, transforming what would have been a time-consuming purification challenge into a straightforward process with minimal cleanup required.
Solution Approach 2:
The invention introduces intermediary chromium-free oxidizing agents that perform the necessary oxidation function without leaving harmful residues. These alternative reagents act as mediators that achieve the oxidation effectiveness of chromium-based agents while being easily removable or non-contaminating, thus eliminating extensive purification requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the synthesis of thionine and thioninium compounds with reduced chromium content, eliminating the need for extensive purification and providing a more reliable pharmaceutical form for long-term therapy.
Implementation Method 1
selective alkylation by reductive amination, in which the corresponding unsubstituted diamine of Formula (4) is reacted with aldehyde/ketone, under reductive amination conditions
Data Source
Figure 1
Figure 2~3
Figure 4
AI summary
The present invention pertains generally to the field of chemical synthesis, and more particularly to methods of chemical synthesis which include the step of preparing a substituted 10H-phenothiazine-3,7-diamine compound of Formula (1) by a step of selective alkylation by reductive amination, in which the corresponding unsubstituted diamine of Formula (4) is reacted with aldehyde/ketone, under reductive amination conditions. The present invention also relates to such methods which incorporate additional subsequent and/or preceding steps, for example, to prepare compounds of Formulae (2) and (3) from compounds of Formula (1), and to prepare compounds of Formula (4) from, for example, compounds of Formulae (5), (6), (7), (8), and (9). Compounds of Formula (1), Formula (2), and Formula (3) are useful, for example, in the treatment of diseases of protein aggregation, such as Alzheimer's disease.